Evidence map›Paper›PMID 39929517›Full record

ArticleBMJ open2025

Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma.

Kristen McParland, Eng-Siew Koh, Benjamin Kong, Hao-Wen Sim, Subotheni Thavaneswaran, Sonia Yip, Elizabeth H Barnes, Mandy L Ballinger, David M Thomas, Richard De Abreu Lourenco and 8 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kristen McParlandThe NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia kristen.mcparland@sydney.edu.au.ORCID http://orcid.org/0009-0002-6606-7032
Eng-Siew KohRadiation Oncology, Liverpool Cancer Therapy Centre, Liverpool, New South Wales, Australia.ORCID http://orcid.org/0000-0002-1664-2513
Benjamin KongThe NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8659-5591
Hao-Wen SimThe NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-2530-0523
Subotheni ThavaneswaranThe NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Sonia YipThe NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Elizabeth H BarnesThe NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Mandy L BallingerOmico, Australian Genomic Cancer Medicine Centre, Sydney, New South Wales, Australia.
David M ThomasOmico, Australian Genomic Cancer Medicine Centre, Sydney, New South Wales, Australia.
Richard De Abreu LourencoCentre for Health Economics Research and Evaluation, University of Technology Sydney, Broadway, New South Wales, Australia.
John SimesThe NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Lucille SebastianOmico, Australian Genomic Cancer Medicine Centre, Sydney, New South Wales, Australia.
Patrick J WheelerThe NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Desma SpyridopoulosThe NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Cynthia HawkinsDivision of Hematology/Oncology, The Hospital for Sick Children, Institute of Medical Sciences, The University of Toronto, Toronto, Ontario, Canada.
Marshall PitzUniversity of Manitoba, Winnipeg, Manitoba, Canada.
Christopher O'CallaghanCanadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.
Hui K GanMedical Oncology, Olivia Newton-John Cancer Centre, Heidelberg, Victoria, Australia.ORCID http://orcid.org/0000-0001-7319-8546

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAll grade 2/3 gliomas are incurable and at the time of inevitable relapse, patients have significant unmet needs with few effective treatments. This study aims to improve outcomes by molecular profiling of patients at relapse, then matching them with the best available drug based on their molecular profile, maximising the chances of patient benefit while simultaneously testing multiple novel drugs. METHODS AND ANALYSIS: Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2) will be an international, phase 2, multicentre, open-label, biomarker-directed, umbrella clinical trial for recurrent isocitrate dehydrogenase mutant, histologically grade 2/3 gliomas. Investigational treatment will be assigned based on molecular profiling of contemporaneous tissue obtained at disease relapse using next-generation sequencing. LUMOS-2 will begin with three therapeutic treatment arms: paxalisib, cadonilimab and selinexor. Patient molecular profiles will be assessed by an expert, multidisciplinary Molecular Tumour Advisory Panel. Patients whose molecular profile is considered suitable for a targeted agent like paxalisib will be allocated to that arm, others will be randomised to the available arms of the trial. The primary endpoint is progression-free survival at 6 months. Secondary objectives include assessment of overall survival, response rate, safety and quality of life measures. Two additional therapeutic arms are currently in development. ETHICS AND DISSEMINATION: Central ethics approval was obtained from the Sydney Local Health District Ethics Review Committee, Royal Prince Alfred Hospital Zone, Sydney, Australia (Approval: 2022/ETH02230). Other clinical sites will provide oversight through local governance processes, including obtaining informed consent from suitable participants. A report describing the results of the study will be submitted to international meetings and peer-reviewed journals. TRIAL REGISTRATION NUMBER: ACTRN12623000096651.

Indexed as

Brain NeoplasmsGliomaIsocitrate DehydrogenaseNeoplasm Recurrence, LocalBiomarkers, TumorClinical Trials, Phase II as TopicHumansMolecular Targeted TherapyMulticenter Studies as TopicMutationNeoplasm GradingProspective StudiesBiomarkers, TumorIsocitrate DehydrogenaseCancer geneticsClinical TrialDrug TherapyHead & neck tumours

Identifiers

PMID39929517
PMCPMC11815451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.